NCT04990024 The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
| NCT ID | NCT04990024 |
| Status | Recruiting |
| Phase | — |
| Sponsor | American University of Beirut Medical Center |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2021-07-01 |
| Primary Completion | 2025-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2021-07-01 with a primary completion date of 2025-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients initiating Semaglutide for weight management, the objective is to compare the effect of the Mediterranean diet and the high protein/low carbohydrate (HP/LC) diet CV parameters, namely arterial stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), and visceral adipose tissue, in addition to other metabolic indicators.
Eligibility Criteria
Inclusion Criteria: * Men and premenopausal women, 18-49 years, with obesity defined as BMI ≥ 30 kg/m2 * Upon the initiation of Semaglutide (within the first 1-4 weeks) for medical weight management, for clinical purposes, as advised by the primary physician * Able to commit for a 6-month trial visits Exclusion Criteria: * Pregnant women * Patients who are taking or have taken other weight reducing drug therapies in the previous 6 months * Patients who have undergone metabolic weight loss surgery * Patients known to have diabetes (HbA1c ≥6.5% at screening) * Patients with uncontrolled hypertension * Patients with uncontrolled cardiac disease, pulmonary, renal or liver diseases, active cancer or psychiatric diseases * Patients with excessive alcohol intake, defined as ≥ 2 glasses per day * Patients known to have uncontrolled/ untreated thyroid disorders. * Patients with cushing disease or polycystic ovaries, and those with neuro-endocrine or drug induced obesity (such as anti-psychotic, steroids, hormonal therapy): Such patients are resistant to weight loss, and they need treatment of their primary disease and/or cessation of the culprit medication to lose weight * Patients with untreated gout * Patients who have undergone bariatric surgery
Contact & Investigator
Marlene Chakhtoura, MD, MSc
PRINCIPAL INVESTIGATOR
American University of Beirut Medical Center
Frequently Asked Questions
Who can join the NCT04990024 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 49 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04990024 currently recruiting?
Yes, NCT04990024 is actively recruiting participants. Contact the research team at mc39@aub.edu.lb for enrollment information.
Where is the NCT04990024 trial being conducted?
This trial is being conducted at Beirut, Lebanon.
Who is sponsoring the NCT04990024 clinical trial?
NCT04990024 is sponsored by American University of Beirut Medical Center. The principal investigator is Marlene Chakhtoura, MD, MSc at American University of Beirut Medical Center. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.